anti-EX02 autologous CAR T-cell therapy (Zeno Therapeutics)

N/A

Report date: 2025/06/11 10:21:01

Base Information

Drug Nameanti-EX02 autologous CAR T-cell therapy (Zeno Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of Action5'-3' Exoribonuclease 1 modulatorsT lymphocytes stimulantsImmunostimulants

Targets5'-3' Exoribonuclease 1

Therapy Area/IndicationsPancreatic NeoplasmsBile Duct Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZeno Therapeutics Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesZeno Therapeutics Pte Ltd

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsBile Duct Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A